Senseonics Holdings, Inc. is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes. The Company's Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user's mobile device, such as a smartphone, Apple Watch or tablet.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Medical Devices
- Sub-Industry: N/A
- Symbol: ARCA:SENS
- CUSIP: N/A
- Web: www.senseonics.com
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -2,755.95%
- Return on Equity: -510.81%
- Return on Assets: -162.96%
- Debt-to-Equity Ratio: 1.60%
- Current Ratio: 3.03%
- Quick Ratio: 2.81%
Frequently Asked Questions for Senseonics Holdings (ARCA:SENS)
What is Senseonics Holdings' stock symbol?
Senseonics Holdings trades on the ARCA under the ticker symbol "SENS."
Who are some of Senseonics Holdings' key competitors?
Some companies that are related to Senseonics Holdings include Keryx Biopharmaceuticals (KERX), Aduro Biotech (ADRO), Heron Therapeutics (HRTX), Reata Pharmaceuticals (RETA), TG Therapeutics (TGTX), Versartis (VSAR), La Jolla Pharmaceutical Company (LJPC), Crispr Theraptc (CRSP), Cytokinetics, Incorporated (CYTK), PetIQ (PETQ), U.S. Physical Therapy (USPH), AtriCure (ATRC), Revance Therapeutics (RVNC), Audentes Therapeutics (BOLD), CryoLife (CRY), Ignyta (RXDX), Alder BioPharmaceuticals (ALDR) and LeMaitre Vascular (LMAT).
Who are Senseonics Holdings' key executives?
Senseonics Holdings' management team includes the folowing people:
- Stephen P. DeFalco, Independent Chairman of the Board
- Timothy T. Goodnow Ph.D., President, Chief Executive Officer, Director
- Raymond Donald Elsey, Chief Financial Officer, Treasurer, Secretary
- Mukul Jain Ph.D., Chief Operating Officer, Principal Operating Officer
- Mirasol Panlilio, Vice President - Global Sales and Marketing
- Lynne Kelley M.D., Chief Medical Officer
- M. James E. Barrett Ph.D., Independent Director
- Edward J. Fiorentino, Independent Director
- Peter Justin Klein M.D., J.D., Independent Director
- Douglas S. Prince, Independent Director
How do I buy Senseonics Holdings stock?
MarketBeat Community Rating for Senseonics Holdings (ARCA SENS)MarketBeat's community ratings are surveys of what our community members think about Senseonics Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Senseonics Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Senseonics Holdings (ARCA:SENS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Senseonics Holdings (ARCA:SENS)
(Data available from 9/22/2015 forward)
|9/27/2016||B. Riley||Reiterated Rating||Buy|
Earnings History for Senseonics Holdings (ARCA:SENS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Senseonics Holdings (ARCA:SENS)
2017 EPS Consensus Estimate: ($0.57)
2018 EPS Consensus Estimate: ($1.08)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Senseonics Holdings (ARCA:SENS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Senseonics Holdings (ARCA:SENS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Senseonics Holdings (ARCA:SENS)
Latest Headlines for Senseonics Holdings (ARCA:SENS)